Northwest Biotherapeutics, Inc. filed its 10-K on Mar 01, 2022 for the period ending Dec 31, 2021. In this report its auditor, Cherry, Bekaert & Holland, LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.432 USD | +2.86% |
|
-6.86% | -38.37% |
May. 10 | Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Mar. 21 | Northwest Biotherapeutics, Inc. Appoints Pat Sarma to Its Board of Directors | CI |
1st Jan change | Capi. | |
---|---|---|
-38.37% | 530M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- NWBO Stock
- News Northwest Biotherapeutics, Inc.
- Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt